These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 24325579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
    Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ.
    Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW.
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [Abstract] [Full Text] [Related]

  • 5. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
    Kim BG, Park NH, Lee SB, Jeon S, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW.
    Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN, HepNet.Greece Study Group.
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 12. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH, C-TEAM study group and the Taiwan Liver Diseases Consortium.
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY.
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [Abstract] [Full Text] [Related]

  • 17. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
    Ju YC, Jun DW, Choi J, Saeed WK, Lee HY, Oh HW.
    World J Gastroenterol; 2018 Oct 28; 24(40):4606-4614. PubMed ID: 30386110
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.
    J Viral Hepat; 2013 Jul 28; 20(7):502-9. PubMed ID: 23730844
    [Abstract] [Full Text] [Related]

  • 19. Lamivudine for patients with chronic hepatitis B and advanced liver disease.
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group.
    N Engl J Med; 2004 Oct 07; 351(15):1521-31. PubMed ID: 15470215
    [Abstract] [Full Text] [Related]

  • 20. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP.
    Aliment Pharmacol Ther; 2014 Dec 07; 40(11-12):1262-9. PubMed ID: 25312649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.